Successful submission of additional data to US FDA
TRISTEL plc
("Tristel" or the "Company")
Successful submission of additional data to the US FDA
Additional Information Request completed on-time for De Novo submission
FDA decision expected before 30 June 2023
Tristel plc (AIM: TSTL), the manufacturer of infection prevention products utilising proprietary chlorine dioxide technology, announces that it has successfully submitted the additional data requested by the US Food and Drug Administration (FDA) to enable the FDA's decision to grant market clearance for its Duo ULT high-level disinfectant. A decision is expected before 30 June 2023.
In September last year, the Company received the FDA's detailed response to its De Novo submission made in June 2022. The agency grants the applicant a 180-day period in which to generate and submit the additional data requested. Tristel has successfully accomplished this within the agreed timescale.
The FDA will now commence its final review of the De Novo submission and the agency's internal rules require it to make its decision by the Company's financial year-end.
The FDA approval will enable Duo's use for high-level disinfection of intra-cavity ultrasound probes. Duo is already approved by the US Environmental Protection Agency for use on skin-surface ultrasound transducers.
Disinfection of ultrasound probes and transducers accounts for approximately 40% of Tristel's global revenue. The United States is the largest single ultrasound market in the world and access to the US market will be a significant inflection point for the Company.
The Company has already established a manufacturing base in North America and has put in place nationwide distribution in anticipation of FDA clearance.
Paul Swinney, Chief Executive of Tristel, said: "We have been on a five-year journey to gain FDA approval and submitting this last data set is an important milestone for the Company. If we are successful in June, we will be able to introduce an innovative and lower cost decontamination product to the United States healthcare market, significantly increasing our future global revenue and profit potential."
|
Tristel plc |
|
|
Paul Swinney, Chief Executive |
Tel: 01638 721 500 |
|
Liz Dixon, Chief Financial Officer |
|
|
|
|
|
finnCap |
|
|
Geoff Nash/Charles Beeson, Corporate Finance |
Tel: 020 7220 0500 |
|
Alice Lane, Corporate Broking |
|
|
|
|
|
Walbrook PR Ltd |
Tel: 020 7933 8780 or tristel@walbrookpr.com |
|
Paul McManus / Lianne Applegarth |
Mob: 07980 541 893 / 07584 391 303 |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund